
|Articles|September 25, 2014
- Gynecologic Cancers (Issue 1)
- Volume 1
- Issue 1
Trabectedin as a Treatment Option for Patients with Ovarian Cancer
Author(s)Bradley Monk, MD
Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses trabectedin as a potential agent to treat ovarian cancer.
Advertisement
Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses trabectedin as a potential agent to treat ovarian cancer.
Read about research into ovarian cancer > >
Articles in this issue
about 11 years ago
The Role of Molecular Testing in Gynecologic Cancersabout 11 years ago
Dream Team Aims To Change the Face of Ovarian Cancer Researchabout 11 years ago
On The Horizon for Ovarian Cancer: Potentially Promising Treatmentsabout 11 years ago
Cediranib Versus Olaparib in Recurrent Platinum-Sensitive Ovarian CancerAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5








































